Deep Track Capital IMA Position
Exited3-Fund ConvergenceDeep Track Capital exited their position in ImageneBio, Inc. (IMA) in Q4 2025, after holding the stock for 2 quarters.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
IMA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About ImageneBio, Inc.
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Full company profile →Deep Track Capital IMA Position History
Frequently Asked Questions
Does Deep Track Capital own IMA?
No. Deep Track Capital exited their position in ImageneBio, Inc. (IMA) in Q4 2025. They previously held the stock for 2 quarters.
How many hedge funds own IMA?
3 specialist biotech hedge funds currently hold IMA, including OrbiMed Advisors, BVF Partners, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy IMA?
Deep Track Capital's position in IMA was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's IMA position increasing or decreasing?
Deep Track Capital completely exited their IMA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →